ERK inhibitor - Eli Lilly and Company
Latest Information Update: 28 May 2022
At a glance
- Originator Eli Lilly and Company
- Class Antineoplastics; Small molecules
- Mechanism of Action Extracellular signal-regulated MAP kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 May 2022 No recent reports of development identified for phase-I development in Cancer in USA
- 24 Apr 2019 Phase-I clinical trials in Cancer in USA before April 2019 (Eli Lilly pipeline, May 2019)